Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485252 | 0.79 | CYSLTR2 (0.45) | CYSLTR2CYSLTR1MAPT | |
| SCHEMBL6477798 | 0.78 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1 | |
| SCHEMBL6476719 | 0.77 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL6484212 | 0.76 | CYSLTR2 (0.50) | CYSLTR2CYSLTR1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL6477679 | 0.76 | F9 (0.64) | F9F10SMN1; SMN2MAPTHPGD | |
| SCHEMBL6486039 | 0.76 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1 | |
| SCHEMBL6476521 | 0.76 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1 | |
| SCHEMBL6483345 | 0.76 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1 | |
| SCHEMBL6476503 | 0.76 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1SMN1; SMN2MAPTHPGD | |
| SCHEMBL6486507 | 0.75 | MCL1 (0.45) | CYSLTR2CYSLTR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933322-B2 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2005-08-23 | — | — | US | disclosed |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | INSR, GPR119, SLC5A1 | F9 1763/4885F10 2591/4885CYSLTR2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.